← TrialMatch
HomeTrials

Renal Ultrasound Response After Chocolate Consumption

The consumption of dark chocolate (DC) has antihypertensive (3) and anti-inflammatory effects. Some studies also suggest that dark chocolate may also have cardiovascular benefits, but its physiological effects on the kidneys have not been studied in detail. In this randomized, single-blinded, controlled, monocentric cr

Condition(s)Chocolate Consumption
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryThe consumption of dark chocolate (DC) has antihypertensive (3) and anti-inflammatory effects. Some studies also suggest that dark chocolate may also have cardiovascular benefits, but its physiological effects on the kidneys have not been studied in detail. In this randomized, single-blinded, controlled, monocentric cross-over study we will investigate whether the ingestion of a single dose of dark chocolate (g/kg, max 70g) leads to alterations in renal perfusion and blood pressure two hours after its consumption in healthy volunteers and patients suffering from chronic kidney disease. The Doppler-ultrasound assessed renal resistive index (RRI) will be used at baseline and two hours after chocolate consumption as an indirect measure of renal perfusion. Blood pressure and heart rate will be
Who can participateInclusion Criteria for healthy volunteers: * Age ≥ 18 years old * ability to understand the study protocol and to sign an informed consent. Inclusion criteria for CKD patients: * Age ≥18 years old, * CKD stage 1-3, * ability to understand the study protocol and to sign an informed consent Exclusion Criteria: * Lactose or cocoa intolerance, * Diabetes, * any severe digestive issue and liver disease, * history of kidney stones, * inability to follow the procedures of the study, e.g. due to language problems, dementia, etc. * pregnant women * healthy volunteers taking antihypertensive medication * healthy volunteers having a known kidney malformation or abnormality * healthy volunteers with albuminuria and/or hematuria in the urine sample. * CKD patients with an eGFR\<30ml/min/1.73m2 * CKD pa
Ages18 Years
SexAll
Accepts healthy volunteersYes
Lead sponsorGregoire Wuerzner; MD
LocationsLausanne, Canton of Vaud, Switzerland; Lausanne, Canton of Vaud, Switzerland
Start date2023-02-22
NCT IDNCT05755217
Official listinghttps://clinicaltrials.gov/study/NCT05755217

🔍 Search all trials →